MS
BOLT icon

Maven Securities’s Bolt Biotherapeutics BOLT Stock Holding History

Maven Securities’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,259
Closed -$390K – 1067
2021
Q2 		$390K Buy
+1,259
New +$511K 0.02% 758

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Maven Securities's BOLT Position: Q3 2021 in Review

Maven Securities sold out of Bolt Biotherapeutics (BOLT) in Q3 2021, closing a stake of 1,259 shares — an estimated $390K sold.

Maven Securities first reported a position in BOLT in Q2 2021 and held it in 1 quarter. The position peaked at $390K in Q2 2021. 71 funds tracked by Wall St. Rank hold BOLT as of Q3 2021.

  • Maven Securities reported no remaining Bolt Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 1,259 Bolt Biotherapeutics shares in Q3 2021, an estimated $390K.
  • Maven Securities first reported a position in Bolt Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Maven Securities's Bolt Biotherapeutics position peaked at $390K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.